Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy.
Sikiric. Predrag P; Drmic. Domagoj D; Sever. Marko M; Klicek. Robert R; Blagaic. Alenka B AB; Tvrdeic. Ante A; Kralj. Tamara T; Kovac. Katarina K KK; Vukojevic. Jaksa J; Siroglavic. Marko M; Gojkovic. Slaven S; Krezic. Ivan I; Pavlov. Katarina H KH; Rasic. Domagoj D; Mirkovic. Ivan I; Kokot. Antonio A; Skrtic. Anita A; Seiwerth. Sven S
Key Findings
- BPC‑157 consistently healed various gastrointestinal fistulas (external and internal) in rat models.
- The peptide promoted healing across multiple tissue types (skin, muscle, tendon, ligament, bone, corneal ulcers).
- Its beneficial effects persisted even when healing was impaired by NSAIDs, cysteamine, large‑bowel resection, ulcerative colitis, short‑bowel syndrome, and liver or brain disturbances.
Practical Outcomes
- For biohackers, BPC‑157 may be worth exploring as a gut‑protective and tissue‑repair agent, especially for people dealing with ulcers, surgical gut connections, or chronic inflammation. However, human dosing protocols are not yet established, so any use should be cautious and preferably under medical supervision.
Summary
The review says that BPC‑157, a peptide naturally found in stomach juice, helps heal many kinds of wounds in rats, especially gastrointestinal fistulas and surgical connections, even when healing is made harder by drugs like NSAIDs. It also works on skin, muscle, tendons, bones, and even eye ulcers. While human trials are still limited, the animal data suggest BPC‑157 could be a useful tool for repairing gut leaks and other tissue injuries.
Abstract
This review is focused on the healing of fistulas and stable gastric pentadecapeptide BPC 157. Assuming that the healing of the various wounds is essential also for the gastrointestinal fistulas healing, the healing effect on fistulas in rats, consistently noted with the stable gastric pentadecapeptide BPC 157, may raise several interesting possibilities. BPC 157 is originally an anti-ulcer agent, native to and stable in human gastric juice (for more than 24 h). Likely, it is a novel mediator of Robert's cytoprotection maintaining gastrointestinal mucosal integrity. Namely, it is effective in the whole gastrointestinal tract, and heals various wounds (i.e., skin, muscle, tendon, ligament, bone; ulcers in the entire gastrointestinal tract; corneal ulcer); LD1 is not achieved. It is used in ulcerative colitis clinical trials, and now in multiple sclerosis, and addressed in several reviews. Therefore, it is not surprising that BPC 157 has documented consistent healing of the various gastrointestinal fistulas, external (esophagocutaneous, gastrocutaneous, duodenocutaneous, colocutaneous) and internal (colovesical, rectovaginal). Taking fistulas as a pathological connection, this rescue is verified with the beneficial effects in rats with the various gastrointestinal anastomoses, esophagogastric, jejunoileal, colo-colonic, ileoileal, esophagojejunal, esophagoduodenal, and gastrojejunal. This beneficial effect occurs equally when the gastrointestinal anastomoses are impaired with the application of NSAIDs, cysteamine, large bowel resection, as well as concomitant esophageal, gastric, and duodenal lesions and/or ulcerative colitis presentation, short bowel syndrome progression, liver and brain disturbances presentation. Particular aspects of the BPC 157 healing of the fistulas are especially emphasized.
Study Information
pubmed
2020
2020-04-24T00:00:00.000Z
10.2174/1381612826666200424180139
22
107